Search results (345)
« Back to PublicationsInvestigation and management of thrombocytosis without JAK2, CALR or MPL mutations: A British Society for Haematology Guideline.
Journal article
Godfrey AL. et al, (2026), Br J Haematol, 208, 471 - 485
Redefining the topology of the human bone marrow using augmented spatial transcriptomic analysis
Preprint
Cooper RA. et al, (2025)
Causal relevance of clonal haematopoiesis with cardiac disease and adverse remodelling: a Mendelian randomisation study.
Journal article
Morley AP. et al, (2025), Open Heart, 12
Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNA.
Journal article
Murphy L. et al, (2025), Science, 389
SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2.
Journal article
Cho H-J. et al, (2025), EMBO Mol Med, 17, 2115 - 2136
Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.
Journal article
Wang Z. et al, (2025), Blood, 146, 341 - 355
Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A.
Journal article
Brierley CK. et al, (2025), Nat Genet, 57, 1478 - 1492
Tumor-Infiltrating Clonal Hematopoiesis.
Journal article
Pich O. et al, (2025), N Engl J Med, 392, 1594 - 1608
Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial.
Journal article
McIlroy G. et al, (2025), BMC Cancer, 25
comBO: A combined human bone and lympho-myeloid bone marrow organoid for pre-clinical modelling of haematopoietic disorders
Preprint
Shen Y. et al, (2025)
Multi-endpoint AI morphology model (MEAM) enhances risk prediction for vascular events and disease progression in MPNs
Journal article
Hu X. et al, (2025), BLOOD, 146, 5599 - 5600
HIGH PREVALENCE OF GERMLINE PREDISPOSITION IN PAEDIATRIC MYELODYSPLASTIC SYNDROME: A SINGLE-CENTRE RETROSPECTIVE ANALYSIS
Journal article
Nyiro J. et al, (2025), EJC PAEDIATRIC ONCOLOGY, 6
Interim analysis of promise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib
Journal article
Mead A. et al, (2025), BLOOD, 146, 3794 - 3795
Molecular profiling in MPN: who should have it and why?
Journal article
Chee A. and Mead AJ., (2024), Hematology Am Soc Hematol Educ Program, 2024, 524 - 534
Treatment of the blood cancer polycythemia vera with ruxolitinib in the MAJIC-PV study: a plain language summary.
Journal article
Harrison CN. et al, (2024), Future Oncol, 20, 3365 - 3376